News headlines Recursion Pharmaceuticals reported its Q2 2026 earnings with a narrowed net loss and progress on several clinical programs. The company is advancing in its AI-driven drug discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results